OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22 2023 - 6:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its fourth quarter and full year 2022 financial results after the
close of the U.S. financial markets on Wednesday, March 29th, 2023.
OpGen’s management team will host a live conference call and audio
webcast at 4:30 p.m. Eastern Time to discuss the Company’s
financial results and provide an update on business activities.
Conference Call Details |
|
U.S. Dial-in Number: |
1-877-704-4453 |
|
International Dial-in Number: |
1-201-389-0920 |
|
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1595064&tp_key=d21054e901 |
|
Conference ID: |
13735798 |
|
|
|
Replay Details |
|
U.S. Dial-in Number:
International
Dial-in Number:Replay
PIN: |
1-844-512-29211-412-317-667113735798 |
Following the conclusion of the conference call, a replay will
be available through April 12, 2023. The live, listen-only webcast
of the conference call may also be accessed by visiting the
Investors section of the Company’s website at www.opgen.com. A
replay of the webcast will be available following the conclusion of
the call and will be archived on the Company’s website under
Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine
company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease. Along with our
subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, and AREScloud, as well as the
Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Group afactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024